Procoagulant compound as well as preparation method and application thereof

Abstract

The invention provides a procoagulant compound. The procoagulant compound is a compound obtained by modifying isocyanate with a functional reagent, the functional reagent is a hydroxyl compound or an amino compound containing calcium ions. Calcium ions are introduced into the molecular structure of the compound containing the isocyanate group, so that the procoagulant activity is given to the compound.

Description

Technical Field

[0001] The present invention relates to the technical field of hemostatic materials, and in particular to a procoagulant compound and a preparation method and application thereof. Background Art

[0002] Uncontrolled unexpected bleeding is common in emergency situations such as car accidents and wars, and in medical operations. Massive blood loss can lead to a high mortality rate for the injured and surgical patients. According to statistics, about 39% of people die from bleeding in accidents. In addition, massive bleeding can also induce a series of complications and adverse effects, such as organ failure, infection, and disseminated intravascular coagulation due to lack of blood, which can be life-threatening. Therefore, rapid and effective hemostasis is the key to ensuring the survival of patients with massive bleeding during trauma and surgery.

[0003] Representative hemostatic products at home and abroad are mainly divided into biological products, chitosan and aluminosilicate hemostatic materials. Among them, biological products hemostatic materials are prone to pathogen infection or immune response; chitosan hemostatic materials can cause allergic reactions; aluminosilicate products have a strong exothermic effect, causing secondary damage to patients. In response to the above problems, how to develop excellent medical hemostatic materials and products according to the hemostatic needs of different wounds has aroused widespread interest among scientific researchers.

[0004] Calcium ions play a very important role in the coagulation mechanism. They can not only promote the synthesis and release of coagulation factors VII, IX and X, participate in endogenous and exogenous coagulation, and accelerate hemostasis; they can also participate in the transformation of platelet morphology, cause platelet contraction, and promote the coagulation of blood clots. Southwest University proposed a hemostatic material (CN113968993B) using calcium chloride to prepare alginate porous membrane, but the production process of the above hemostatic material is complicated and the cost is high. Beijing University of Chemical Technology prepared a water-soluble chitosan / nanoparticle CaO2@pSiO2 composite sponge (CN113694247B) using calcium peroxide, and also prepared a chitosan / sodium alginate / fucoidan sulfate composite sponge containing calcium ion hemostatic components (CN111617310B), but the calcium ions in the above materials are physically blended into the material, and the calcium ions are easy to fall off and enter the blood, causing the risk of thrombosis. Summary of the invention

[0005] In view of this, the technical problem to be solved by the present invention is to provide a procoagulant compound and a preparation method and application thereof, which has high procoagulant activity and a simple preparation process.

[0006] To achieve the above-mentioned purpose, the present invention provides a procoagulant compound, which is a compound obtained by modifying isocyanate with a functional reagent;

[0007] The functional agent is a hydroxy compound or an amino compound containing calcium ions.

[0008] The above modification is specifically an amination reaction, in which the hydroxyl or amino group of the functional reagent reacts with the isocyanate, and the reaction formula is:

[0009]

[0010] Here, R' is a group other than the hydroxyl group in the hydroxyl compound containing calcium ions, and it contains calcium ions and may or may not have a hydroxyl group.

[0011] R" is a group other than the amino group in the amino compound containing calcium ions, and it contains calcium ions and may or may not contain an amino group.

[0012] Preferably, the functional agent is selected from one or more of atorvastatin calcium, rosuvastatin calcium, carbaspirin calcium, pitavastatin calcium, calcium pantothenate, calcium L-lactate, calcium glycolate, calcium glycinate, calcium L-threonate, calcium DL-malate, calcium levofolinate, calcium glycerophosphate, calcium glucopyranoate, calcium D(-)-arabinonate, sodium lactobionate calcium salt, calcium hydroxymethionine, calcium DL-3-hydroxybutyrate, calcium L-aspartate, anhydrous calcium dihydrogen phosphate, calcium lactobionate bromide, calcium 2,5-dihydroxybenzenesulfonate and levothyroxine calcium.

[0013] In the present invention, the isocyanate is diisocyanate or polyisocyanate.

[0014] The present invention does not specifically limit the type of the above-mentioned isocyanate. It has two or three isocyanate groups that can react with the hydroxyl or amino group of the functional reagent to introduce calcium ions, and can undergo polymerization reaction with the polyurethane prepolymer during the preparation of the hemostatic polyurethane material, and finally introduce calcium ions into the hemostatic polyurethane material.

[0015] The diisocyanate includes, but is not limited to, one or more of isophorone diisocyanate, diphenylmethane diisocyanate, toluene diisocyanate, 1,5-naphthalene diisocyanate, m-phenylene diisocyanate, p-phenylene diisocyanate, hexamethylene diisocyanate, 1,4-diisocyanate, 2,6-diisocyanate, xylylene diisocyanate, 3,3'-dimethyl-4,4'-biphenyl diisocyanate, 1,3-dimethylcyclohexane and dicyclohexylmethane 4,4'-diisocyanate.

[0016] The polyisocyanate includes, but is not limited to, one or more of triphenylmethane triisocyanate, 1,3-bis(3-isocyanate-4-methylphenyl)-1,3-diazacyclo-2,4-butanedione, 1,3,5-tris(3-isocyanatetolyl)-1,3,5-triazine-2,4,6-trione, benzyl diisocyanate-trimethylolpropane adduct, hexamethylene diisocyanate trimer, hexamethylene diisocyanate dimer, hexamethylene diisocyanate biuret and isophorone diisocyanate trimer.

[0017] The molar ratio of the functional agent to the isocyanate is preferably 1:(2-40).

[0018] The present invention provides a method for preparing the above-mentioned procoagulant compound, comprising the following steps:

[0019] The functional reagent, isocyanate and catalyst are mixed and reacted to obtain a procoagulant compound.

[0020] Preferably, the above method is specifically:

[0021] The functional reagent, isocyanate and catalyst are mixed and reacted, and an organic solvent can be selectively added according to the reaction viscosity to prepare a procoagulant compound.

[0022] Or specifically:

[0023] The functional reagent is dissolved in an organic solvent and mixed with isocyanate under the action of a catalyst to prepare a procoagulant compound.

[0024] Preferably, the organic solvent is one or more of toluene, acetone, dichloromethane, N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, dioxane, cyclohexane, acetonitrile and chloroform. More preferably, it is one or more of N,N-dimethylformamide, toluene and cyclohexane.

[0025] The molar ratio of the organic solvent to the functional agent is preferably (1-500):1.

[0026] The catalyst is preferably one or more of bismuth isooctanoate, potassium isooctanoate, stannous octoate, dibutyltin dilaurate, triethylenediamine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,4-dimethylpiperazine, triethylenediamine, bis(dimethylaminoethyl)ether, dimethylcyclohexylamine, and pentamethyldiethylenetriamine. More preferably, it is one or more of stannous octoate, dibutyltin dilaurate, triethylenediamine, and triethylenediamine.

[0027] The molar ratio of the functional agent, isocyanate and catalyst is preferably 1:(2-40):(0-1).

[0028] The reaction temperature is preferably 40 to 120°C.

[0029] The procoagulant compound provided by the present invention can be used as a functional isocyanate to introduce calcium ions into the main chain of the polyurethane molecule, so that the material has hemostatic functionality and is non-cytotoxic.

[0030] Based on this, the present invention provides the use of the above-mentioned procoagulant compound in the preparation of hemostatic materials.

[0031] The hemostatic material is preferably a hemostatic polyurethane material, including but not limited to a hemostatic polyurethane sponge, a hemostatic polyurethane adhesive, a hemostatic polyurethane elastomer, a hemostatic polyurethane coating, and the like.

[0032] The hemostatic polyurethane elastomer can be prepared into a porous material by physical foaming technology.

[0033] The present invention has no special limitation on the above-mentioned physical foaming technology, which may be a physical foaming technology well known to those skilled in the art. The present invention includes but is not limited to supercritical foaming technology or solid hollow sphere foaming technology.

[0034] The present invention provides a hemostatic polyurethane material, which is prepared by blending and foaming material A and material B;

[0035] The material A is a mixture of a polyurethane prepolymer and the above-mentioned procoagulant compound;

[0036] The material B includes one or more of a chain extender, a foaming agent, a catalyst, an emulsifier and a surfactant.

[0037] The present invention has no particular limitation on the types of the polyurethane prepolymer, chain extender, foaming agent, catalyst, emulsifier and surfactant, and they may be any applicable types known to those skilled in the art.

[0038] In some specific embodiments of the present invention, the polyurethane prepolymer is a polyurethane prepolymer obtained by polymerization reaction of one or more of polyether triol, polycaprolactone diol, polytetramethylene ether glycol, polypropylene oxide ether glycol and a polyisocyanate compound. The polyisocyanate is preferably one or more of toluene diisocyanate, hexamethylene diisocyanate, diphenylmethane diisocyanate, and isophorone diisocyanate trimer.

[0039] The chain extender is preferably one or more of glycerol, polycaprolactone triol, trimethylolpropane, and 1,4-butanediol.

[0040] The foaming agent is preferably deionized water.

[0041] The catalyst is preferably one or more of triethylenediamine, triethylenediamine, stannous octoate, and dibutyltin dilaurate.

[0042] The emulsifier is preferably one or more of sorbitan fatty acid ester and polyoxyethylene sorbitan fatty acid ester.

[0043] The surfactant is preferably one or more of polymerized silicone, polyoxyethylene ether, oxypropylene oxyethylene propylene glycol ether, aliphatic polyoxyethylene (15) ether, polyoxyethylene and polyoxypropylene block polymers.

[0044] Compared with the prior art, the present invention provides a procoagulant compound, which is a compound obtained by modifying isocyanate with a functional reagent; the functional reagent is a hydroxyl compound or an amine compound containing calcium ions. The present invention introduces calcium ions into the molecular structure of the compound containing an isocyanate group, thereby imparting the compound with procoagulant activity.

[0045] The procoagulant compound has the following advantages:

[0046] (1) The preparation method is simple, green and environmentally friendly, the reaction conditions are relatively mild, and the synthesis can be done in one step. The method is simple, the operability is strong, and the step economy is high;

[0047] (2) The substrate range is wide, and more complex procoagulant compounds can be obtained, which are important synthetic intermediates or drug intermediates;

[0048] (3) It has high activity and has the function of improving coagulation efficiency. At the same time, calcium ions will not fall off the material, causing the safety risk of thrombosis, which is of great significance for synthetic hemostatic polyurethane materials. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 This is a picture of the rat femoral artery hemostasis after 3 minutes of commercially available gelatin hemostatic sponge;

[0050] Figure 2 This is a picture of the femoral artery of a rat after 3 minutes of hemostasis using a commercially available ordinary polyurethane sponge;

[0051] Figure 3 This is a picture of the hemostatic polyurethane sponge prepared in Application Example 1 of the present invention after 3 minutes of hemostasis in the femoral artery of a rat. DETAILED DESCRIPTION

[0052] In order to further illustrate the present invention, the procoagulant compound provided by the present invention and its preparation method and application are described in detail below in conjunction with examples.

[0053] Example 1

[0054] Under nitrogen protection, 216.60 g of toluene diisocyanate (a mixture of 80% by mass of 2,4-toluene diisocyanate and 20% by mass of 2,6-toluene diisocyanate) and 0.25 g of triethylenediamine were added to 12.55 g of calcium lactate, and the reaction was stirred at 40° C. until the NCO value stabilized to obtain a procoagulant compound.

[0055] Example 2

[0056] Under nitrogen protection, 47.10 g of toluene diisocyanate (100% by mass of 2,4-toluene diisocyanate) and 0.01 g of stannous octoate were added to 5.95 g of calcium D-pantothenate, and the mixture was stirred at 80° C. to react until the NCO value was stable, thereby obtaining a procoagulant compound.

[0057] Example 3

[0058] Under nitrogen protection, 232.12 g of isophorone diisocyanate and 0.25 g of triethylenediamine were added to 6.16 g of calcium DL-3-hydroxybutyrate, and the mixture was stirred at 60° C. to react until the NCO value was stable, thereby obtaining a procoagulant compound.

[0059] Example 4

[0060] Under nitrogen protection, 54.08 g of hexamethylene diisocyanate and 0.15 g of dibutyltin dilaurate were added to 30.43 g of calcium L-aspartate, and the mixture was stirred at 90° C. to react until the NCO value was stable, thereby obtaining a procoagulant compound.

[0061] Example 5

[0062] Under nitrogen protection, 22.97 g of carbaspirin calcium was dissolved in 100 g of anhydrous N,N-dimethylformamide solution, and then 55.56 g of diphenylmethane diisocyanate and 0.35 g of dibutyltin dilaurate were added, and the mixture was stirred at 120° C. to react until the NCO value was stable, thereby obtaining a procoagulant compound.

[0063] Example 6

[0064] Under nitrogen protection, 111.50 g of isophorone diisocyanate trimer, 0.05 g of triethylenediamine and 123.04 g of toluene solution were added to 11.54 g of calcium glycinate, and the mixture was stirred at 70° C. to react until the NCO value was stable, thereby obtaining a procoagulant compound.

[0065] The procoagulant compounds synthesized in the above examples are synthetic material intermediates. The preferred embodiments of the present invention are described below in conjunction with application examples. However, it should be understood that these descriptions are only to further illustrate the features and advantages of the present invention, rather than to limit the claims of the present invention.

[0066] Application Example 1

[0067] Under nitrogen protection, 23.47g of toluene diisocyanate (a mixture of 80% by mass of 2,4-toluene diisocyanate and 20% by mass of 2,6-toluene diisocyanate) was added to 100g of anhydrous polyether triol (ethylene oxide: propylene oxide is 30:70, and the number average molecular weight is 5000), and the mixture was stirred at 70°C until the NCO value was stable to obtain a prepolymer. Under nitrogen protection, 216.60g of toluene diisocyanate (a mixture of 80% by mass of 2,4-toluene diisocyanate and 20% by mass of 2,6-toluene diisocyanate) and 0.25g of triethylenediamine were added to 12.55g of calcium lactate, and the mixture was stirred at 40°C until the NCO value was stable to obtain a procoagulant compound. 100.00g of deionized water, 3.05g of propylene glycol, 18.53g of polymerized siloxane, 7.88g of polyoxyethylene ether, 6.30g of sorbitan fatty acid ester and 11.21g of polycaprolactone triol were mixed at 15°C to obtain material B. 100.00g of prepolymer was mixed with 60.00g of procoagulant compound and mechanically stirred at 650rpm for 20min to obtain material A. 50.00g of material A and 60.00g of material B were mechanically stirred at 15°C for free foaming at a speed of 1400rpm for 18s, and poured into a 25cm*25cm*0.5cm mold, and the foaming was limited for 30min under a pressure of 15kg to obtain a procoagulant polyurethane sponge material.

[0068] Application Example 2

[0069] Under nitrogen protection, 39.83 g of toluene diisocyanate (100% by mass of 2,4-toluene diisocyanate) was added to 100.00 g of anhydrous polyether triol (ethylene oxide: propylene oxide is 50:50, number average molecular weight is 6000), and the mixture was stirred at 80° C. to react until the NCO value was stable to obtain a prepolymer. Under nitrogen protection, 47.10 g of toluene diisocyanate (100% by mass of 2,4-toluene diisocyanate) and 0.01 g of stannous octoate were added to 5.95 g of calcium D-pantothenate, and the mixture was stirred at 80° C. to react until the NCO value was stable to obtain a procoagulant compound. 100.00g of deionized water, 13.58g of glycerol, 20.96g of oxypropylene glycol ether, 8.47g of aliphatic polyoxyethylene (15) ether, 1.65g of sorbitan fatty acid ester, 1.65g of polyoxyethylene sorbitan fatty acid ester, 2.57g of polyoxyethylene and polyoxypropylene block polymer and 3.85g of polycaprolactone triol were mixed at 25°C to obtain material B. 100.00g of prepolymer was mixed with 50.00g of procoagulant compound and mechanically stirred at 800rpm for 30min to obtain material A. 50.00g of material A and 70.00g of material B were mechanically stirred at 25°C for free foaming at a rotation speed of 1300rpm for 25s, and the procoagulant polyurethane sponge material was obtained after curing.

[0070] Application Example 3

[0071] Under nitrogen protection, add 232.12g of isophorone diisocyanate and 0.25g of triethylenediamine to 6.16g of calcium DL-3-hydroxybutyrate, stir and react at 60°C until the NCO value is stable to obtain a procoagulant compound. Under nitrogen protection, add 47.66g of a procoagulant compound to 160.00g of anhydrous polycaprolactone diol (molecular weight 2000), stir and react at 60°C until the NCO value is stable to obtain a prepolymer mixture. Take 103.83g of the prepolymer mixture, vacuum defoam at 60°C for 15min, then add 1.74g of trimethylolpropane and 5.23g of 1,4-butanediol, stir evenly mechanically, pour into a mold and put into an 80°C blast oven, and after curing, obtain a polyurethane elastic material with procoagulant function.

[0072] Application Example 4

[0073] Under nitrogen protection, 44.82 g of hexamethylene diisocyanate was added to 140.00 g of anhydrous polytetramethylene ether glycol (molecular weight 3000), and then 0.15 g of dibutyltin dilaurate was added thereto after stirring evenly. The mixture was stirred at 70° C. until the NCO value was stable to obtain a prepolymer. Under nitrogen protection, 54.08 g of hexamethylene diisocyanate and 0.15 g of calcium L-aspartate were added to 30.43 g of calcium L-aspartate. g of dibutyltin dilaurate, stirring and reacting at 90°C until the NCO value is stable to obtain a procoagulant compound; taking 100.00g of the prepolymer and mixing it with 21.13g of the procoagulant compound, the mixture is mechanically stirred evenly, and then vacuum defoaming is carried out at 70°C for 15 minutes, and then 14.34g of 1,4-butanediol is added thereto, mechanically stirred evenly, poured into a mold and placed in a 70°C blast oven, and after curing, a polyurethane elastic material with procoagulant function is obtained.

[0074] Application Example 5

[0075] Under nitrogen protection, 33.36 g of diphenylmethane diisocyanate and 0.05 g of dibutyltin dilaurate were added to 120.00 g of anhydrous polyether triol (ethylene oxide: propylene oxide is 30:70, and the number average molecular weight is 6000), and the mixture was stirred and reacted at 75°C until the NCO value was stable to obtain a prepolymer; under nitrogen protection, 22.97 g of carbaspirin calcium was dissolved in 100.00 g of anhydrous N,N-dimethylformamide solution, and then 55.56 g of diphenylmethane diisocyanate and 0.35 g of dibutyltin dilaurate were added, and the mixture was stirred and reacted at 120°C until the NCO value was stable to obtain a procoagulant compound; 100.00 g of the prepolymer was mixed with 17.85 g of the procoagulant compound, and then 1.71 g of 1,4-butanediol was added, and the mixture was stirred at 75°C for 12 hours. The reaction solution was then precipitated in 1 L of ether, washed with ether 2-3 times, the precipitate was collected, and vacuum dried to constant weight to obtain a polyurethane material with procoagulant function.

[0076] Application Example 6

[0077] Under nitrogen protection, 111.50 g of isophorone diisocyanate trimer, 0.05 g of triethylenediamine and 123.04 g of toluene solution were added to 11.54 g of calcium glycinate, and the mixture was stirred and reacted at 70°C until the NCO value was stable to obtain a procoagulant compound; under nitrogen protection, 55.85 g of isophorone diisocyanate trimer, 0.10 g of stannous octoate, 24.61 g of a procoagulant compound, 6.91 g of 1,4-butanediol, 180.00 g of cyclohexane solution and 120.00 g of toluene solution were added to 100.00 g of anhydrous polypropylene oxide ether diol (molecular weight 3000), and the mixture was stirred and reacted at 25°C until a certain viscosity smear was formed, and the mixture was dried at 70°C for 24 hours to obtain a polyurethane coating material with procoagulant function.

[0078] The polyurethane materials prepared in accordance with Examples 1 to 6 were evaluated for in vitro coagulation rate and in vivo hemostatic effect in animals. The sample was a 2cm×2cm×0.5cm square, and commercially available gelatin hemostatic sponges and ordinary polyurethane sponges were purchased as comparative examples. The in vitro coagulation rate experimental method is briefly described as follows: 5 pieces of each of the above materials were taken and cut into a size of 2cm×2cm×0.5cm (the positive control was 0.2mL distilled water), and placed in 12-well plates, respectively, and 300μL of anticoagulated rabbit blood was added to each well. Incubate in a 37°C constant temperature incubator for 30 minutes, take out and add 5mL of distilled water to each well. After shaking for 5 minutes, all the liquid in each well was taken out and its absorbance value at 545nm was measured. The experimental method of the in vivo hemostasis effect of animals is briefly described as follows: 80 albino rats were randomly divided into 8 groups (10 rats in each group). After the rats were anesthetized, the hair in the groin was shaved with a hair pusher and disinfected with iodine cotton balls; an incision was made at one side of the groin, and the fascia layer and the femoral artery and vein branches were peeled off to expose the femoral aorta. A small incision was made at the root of the femoral artery, and the incision was 1 / 3 of the artery diameter upward. After free bleeding for 30 seconds, a sample of 2cm×2cm×0.5cm was used to cover the incision surface, and a 100g weight was used to press and stop bleeding. The material was uncovered every 3 minutes to observe the hemostasis effect until there was no blood oozing out 3 minutes after the sponge and weight were removed, which was the end point of hemostasis. The total time of successful hemostasis of each group of rats was recorded, and the number of rats with successful hemostasis within 3 minutes was recorded. The specific results are shown in Table 1.

[0079] Table 1 Performance of hemostatic polyurethane materials in application examples 1 to 6

[0080]

[0081] The above results show that the hemostatic polyurethane materials prepared in Application Examples 1 to 6 have higher in vitro coagulation rates and shorter in vivo hemostasis times compared to commercially available gelatin hemostatic sponges and ordinary polyurethane sponges, that is, the polyurethane materials prepared in Application Examples 1 to 6 have better hemostatic effects. Therefore, the procoagulant compounds described in the present invention have greater application value.

[0082] The above embodiments are only used to help understand the method and core idea of ​​the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.

Claims

1. A procoagulant compound, characterized in that A compound obtained by modifying isocyanate with a functional reagent; The functional agent is a hydroxy compound or an amino compound containing calcium ions.

2. The procoagulant compound according to claim 1, characterized in that The functional agent is selected from one or more of atorvastatin calcium, rosuvastatin calcium, carbaspirin calcium, pitavastatin calcium, calcium pantothenate, calcium L-lactate, calcium glycolate, calcium glycinate, calcium L-threonate, calcium DL-malate, calcium levofolinate, calcium glycerophosphate, calcium glucopyranoate, calcium D(-)-arabinonate, sodium lactobionate calcium salt, calcium hydroxymethionine, calcium DL-3-hydroxybutyrate, calcium L-aspartate, anhydrous calcium dihydrogen phosphate, calcium lactobionate bromide, calcium 2,5-dihydroxybenzenesulfonate and levothyroxine calcium.

3. The procoagulant compound according to claim 1, characterized in that The isocyanate is a diisocyanate or a polyisocyanate.

4. The method for preparing the procoagulant compound according to any one of claims 1 to 3, comprising the following steps: The functional reagent, isocyanate and catalyst are mixed and reacted to obtain a procoagulant compound.

5. The preparation method according to claim 4, characterized in that: The catalyst is selected from one or more of bismuth isooctanoate, potassium isooctanoate, stannous octoate, dibutyltin dilaurate, triethylenediamine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,4-dimethylpiperazine, triethylenediamine, bis(dimethylaminoethyl) ether, dimethylcyclohexylamine, and pentamethyldiethylenetriamine.

6. The preparation method according to claim 4, characterized in that: The molar ratio of the functional reagent, isocyanate and catalyst is 1:(2-40):(0-1).

7. Use of the procoagulant compound according to any one of claims 1 to 3 in the preparation of hemostatic polyurethane materials.

8. A hemostatic polyurethane material, prepared by blending and foaming material A and material B; The material A is a mixture of a polyurethane prepolymer and the procoagulant compound according to any one of claims 1 to 3; The material B includes one or more of a chain extender, a foaming agent, a catalyst, an emulsifier and a surfactant.

9. The hemostatic polyurethane material according to claim 8, characterized in that: The hemostatic polyurethane material is a hemostatic polyurethane sponge, a hemostatic polyurethane adhesive, a hemostatic polyurethane elastomer or a hemostatic polyurethane coating.

10. The hemostatic polyurethane material according to claim 9, characterized in that: The hemostatic polyurethane elastomer is prepared into a porous material by physical foaming technology; The physical foaming technology is a supercritical foaming technology or a solid hollow ball foaming technology.

Images